12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TOL-3021: Phase II data

A blinded, dose-escalation Phase II trial in 80 adult Type I diabetics showed that all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to placebo. Specifically, the 1 mg dose of TOL-3021 for 12 weeks led to a significant 19.5% increase in C-peptide levels from baseline to week 15 vs. an 8.8% reduction for...

Read the full 302 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >